Pharming Group N.V.

ENXTAM:PHARM Stock Report

Market Cap: €789.6m

Pharming Group Dividends and Buybacks

Dividend criteria checks 0/6

Pharming Group does not have a record of paying a dividend.

Key information

n/a

Dividend yield

-2.6%

Buyback Yield

Total Shareholder Yield-2.6%
Future Dividend Yieldn/a
Dividend Growthn/a
Next dividend pay daten/a
Ex dividend daten/a
Dividend per sharen/a
Payout ration/a

Recent dividend and buyback updates

No updates

Recent updates

Analysis Article • Sep 08

Pharming Group N.V. (AMS:PHARM) Surges 26% Yet Its Low P/S Is No Reason For Excitement

Pharming Group N.V. ( AMS:PHARM ) shareholders have had their patience rewarded with a 26% share price jump in the last...
Analysis Article • May 10

There's No Escaping Pharming Group N.V.'s (AMS:PHARM) Muted Revenues Despite A 29% Share Price Rise

Pharming Group N.V. ( AMS:PHARM ) shares have had a really impressive month, gaining 29% after a shaky period...
Analysis Article • Dec 21

Pharming Group N.V. (AMS:PHARM) Held Back By Insufficient Growth Even After Shares Climb 26%

The Pharming Group N.V. ( AMS:PHARM ) share price has done very well over the last month, posting an excellent gain of...
Analysis Article • Feb 14

Revenues Working Against Pharming Group N.V.'s (AMS:PHARM) Share Price

With a price-to-sales (or "P/S") ratio of 3.4x Pharming Group N.V. ( AMS:PHARM ) may be sending very bullish signals at...
Analysis Article • Nov 11

Health Check: How Prudently Does Pharming Group (AMS:PHARM) Use Debt?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Analysis Article • Aug 23

Pharming Group N.V. (AMS:PHARM) Shares Could Be 49% Below Their Intrinsic Value Estimate

Key Insights The projected fair value for Pharming Group is €2.29 based on 2 Stage Free Cash Flow to Equity Current...
Analysis Article • Jun 20

Health Check: How Prudently Does Pharming Group (AMS:PHARM) Use Debt?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...
Analysis Article • Mar 16

Is Pharming Group (AMS:PHARM) Using Too Much Debt?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Analysis Article • Feb 17

Pharming Group N.V.'s (AMS:PHARM) Intrinsic Value Is Potentially 41% Above Its Share Price

In this article we are going to estimate the intrinsic value of Pharming Group N.V. ( AMS:PHARM ) by estimating the...

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if PHARM's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PHARM's dividend payments have been increasing.

Dividend Yield vs Market

Pharming Group Dividend Yield vs Market
How does PHARM dividend yield compare to the market?
SegmentDividend Yield
Company (PHARM)n/a
Market Bottom 25% (NL)2.6%
Market Top 25% (NL)5.0%
Industry Average (Biotechs)2.2%
Analyst forecast (PHARM) (up to 3 years)n/a

Notable Dividend: Unable to evaluate PHARM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate PHARM's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate PHARM's payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as PHARM has not reported any payouts.

Discover strong dividend paying companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/24 20:48
End of Day Share Price 2026/05/22 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Pharming Group N.V. is covered by 12 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Whitney IjemCanaccord Genuity
John SavinEdison Investment Research
Simon ScholesFirst Berlin Equity Research GmbH